Patent US2078910A successfully refreshed from Google Patents.
US4491575A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compressed products with retarded release of active substance, a process for their preparation and a process for the long-term administration of medicaments
Assignee: PCD Polymere GmbH
•
Filing: 1983-10-06
•
Granted: 1985-01-01
•
Expires: 2003-10-06
Abstract
Abstract Pharmaceutical composition for long-term oral or parenteral administration and adapted to slowly release the pharmaceutically active substance, comprising a therapeutically-active amount of a pharmaceutically-active substance homogeneously mixed with at least 20% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance; a process for preparing such composition in compressed form and a process for the long-term administration of such composition.
Inventors
- 👤 Werner Korsatko
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:14
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
46 words
Compressed products with retarded release of active substance for long-term oral or parenteral administration of medicaments, containing a homogeneous mixture of a pharmaceutically active substance in a therapeutically effective amount with at least 20% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance.
Claim 2
Dependent Claim
46 words
Compressed products with retarded release of active substance for long-term oral or parenteral administration of medicaments, containing a homogeneous mixture of a pharmaceutically active substance in a therapeutically effective amount with at least 20% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance.
Claim 3
Dependent Claim
20 words
Compressed products according to claim 1 in which the poly-D(-)-3-hydroxybutyric acid has a molecular weight of from 25,000 to 1,000,000.
Claim 4
Dependent Claim
38 words
Compressed products according to claim 1, suitable for long-term oral administration of medicaments, containing a homogeneous mixture of the pharmaceutically active substance with 20 to 40% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance.
Claim 5
Dependent Claim
38 words
Compressed products according to claim 1 suitable for long-term parenteral administration of medicaments, containing a homogeneous mixture of the pharmaceutically active substance with 60 to 95% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance.
Claim 6
Dependent Claim
21 words
Compressed products according to claim 1 in which the homogeneous mixture contains auxiliaries and additives customary in the techniques of formulation.
Claim 7
Dependent Claim
68 words
Process for the preparation of compressed products with retarded release of active substance for long-term oral or parenteral administration of medicaments by mixing and then homogenising a pharmaceutically active substance in a therapeutically effective amount with at least 20% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance, and compressing the homogenised mixture to form compressed products under a pressure of 1 to 20 tonnes.
Claim 8
Dependent Claim
68 words
Process for the preparation of compressed products with retarded release of active substance for long-term oral or parenteral administration of medicaments by mixing and then homogenising a pharmaceutically active substance in a therapeutically effective amount with at least 20% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance, and compressing the homogenised mixture to form compressed products under a pressure of 1 to 20 tonnes.
Claim 9
Dependent Claim
15 words
Process according to claim 6 in which the homogenised mixture is compressed to form tablets.
Claim 10
Dependent Claim
18 words
Process according to claim 6 in which the homogenised mixture is compressed to form cores of coated tablets.
Claim 11
Dependent Claim
47 words
Process according to claim 6 in which the pharmaceutically active substance in a therapeutically effective amount is mixed with 60 to 95% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance, and the mixture is homogenised and compressed to form implants for parenteral administration.
Claim 12
Dependent Claim
47 words
Process according to claim 6 in which the pharmaceutically active substance in a therapeutically effective amount is mixed with 20 to 40% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance, and the mixture is homogenised and compressed to form tablets for oral administration.
Claim 13
Dependent Claim
55 words
Process for the controlled long-term administration of medicaments to humans and animals, comprising the administration of compressed products which contain a pharmaceutically active substance in the therapeutically effective amount required for the period of treatment in a homogeneous mixture with at least 20% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance.
Claim 14
Dependent Claim
55 words
Process for the controlled long-term administration of medicaments to humans and animals, comprising the administration of compressed products which contain a pharmaceutically active substance in the therapeutically effective amount required for the period of treatment in a homogeneous mixture with at least 20% by weight of poly-D(-)-3-hydroxybutyric acid relative to the amount of active substance.
Claim 15
Dependent Claim
18 words
Process according to claim 11 in which the compressed product used is a tablet which is administered orally.
Claim 16
Dependent Claim
83 words
Process according to claim 11 for the single, controlled long-term administration of medicaments, comprising the subcutaneous implantation of a compressed product for the treatment of humans or animals over several weeks, which compressed product contains the therapeutically effective amount of the medicament required for the period of treatment and contains at least 60% by weight of poly-D(-)-3-hydroxybutyric acid, the content of poly-D(-)-3-hydroxybutyric acid in the compressed product being selected such that the desired dose of the active substance is released within one day.
References Cited (Backward Citations)
US3887699A
Cited
US4419340A
Cited
US3773919A
Cited
GB1351409A
Cited
US4351337A
Cited
US3991766A
Cited
US3976071A
Cited
US4118470A
Cited
US4328204A
Cited
WO1978000011A1
Cited
DE2836044A1
Cited
US4331652A
Cited
US4333919A
Cited
US4293539A
Cited
GB2077103A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-01-01 | 1988-07-02 | 1989-01-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-01-01 | 1992-07-02 | 1993-01-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-01-01 | 1996-07-02 | 1997-01-01 | $7700.00 | Window Closed / Lapsed |